全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Na Young Jang , Dan Hyo Kim , Bong Jun Cho ...
来源:[J].BMC Cancer(IF 3.333), 2015, Vol.15 (1)Springer
摘要:... Therefore, we assessed the radiosensitizing effect, and the underlying mechanism of combination treatment with PARP inhibitor olaparib and PI3K inhibitor PI-103 in BRCA-proficient TNBC cells.(#br) Methods(#br)MDA-MB-435S cells were divided into four treatment groups, irradi...
作者:De Felice F , Tombolini V , Marampon F ...
来源:[J].Drug Design, Development and Therapy(IF 3.486), 2017, Vol.Volume11, pp.547-552DOAJ
摘要:... Olaparib is an oral PARP inhibitor that blocks DNA repair pathway and coupled with BRCA mutated-disease results in tumor cell death. In phase II clinical trials, including patients with advanced castration-resistant PC, olaparib seems to be efficacious and well tolerated. ...
作者:Mohamed A Ghonim , Kusma Pyakurel , Salome V Ibba ...
来源:[J].Journal of Translational Medicine(IF 3.459), 2015, Vol.13 (1)Springer
摘要:... Olaparib, a PARP inhibitor, was recently introduced in clinical trials against cancer. The objective of the present study was to examine the efficacy of olaparib in blocking established allergic airway inflammation and hyperresponsiveness similar to those observed in hum...
作者:Viviane C. Ruiz-Schutz , Larissa M. Gomes , Rodrigo C. Mariano ...
来源:[J].Critical Reviews in Oncology / Hematology(IF 4.637), 2019, Vol.141, pp.163-173Elsevier
摘要:... Olaparib is FDA-approved for advanced breast cancer and advanced ovarian cancer patients. Fatigue and anemia are among the most common cancer and treatment-related symptoms. Therefore, we conducted a meta-analysis of randomized controlled trials (RCT) to characterize the i...
作者:Luc Dirix , Helen Swaisland , Henk M.W. Verheul ...
来源:[J].Clinical Therapeutics(IF 2.23), 2016, Vol.38 (10), pp.2286-2299Elsevier
摘要:Abstract(#br)Purpose(#br)The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrated efficacy in patients with BRCA -mutated ovarian cancer, is mediated by cytochrome P450 (CYP) enzymes (predominantly CYP3A4/5). We assessed the poten...
作者:Xu K , Chen Z , Cui Y ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2015, Vol.2015 (default), pp.3047-3054DOAJ
摘要:... Methods: A cell counting kit-8 assay was used to determine the sensitivity of CRC cells to olaparib and/or oxaliplatin. The gene and protein expressions of PARP1 and the gamma histone variant H2AX (ΓH2AX) were measured by real-time quantitative polymerase chain reaction and...
作者:Alecu I , Milenkova T , Turner SR
来源:[J].Drug Design, Development and Therapy(IF 3.486), 2018, Vol.Volume 12, pp.347-348DOAJ
摘要:... The authors concluded that olaparib resulted in a higher incidence of severe (common terminology criteria for adverse events [CTCAE] grade $3) neutropenia when compared with niraparib and veliparib; however, these conclusions are based on inappropriate and incomplete comparis...
作者:Ymera Pignochino , Federica Capozzi , Lorenzo D’Ambrosio ...
来源:[J].Molecular Cancer(IF 5.134), 2017, Vol.16 (1)Springer
摘要:Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action. It binds to minor groove of DNA inducing single- and double-strand-break...
作者:Christian Rolfo , Helen Swaisland , Karin Leunen ...
来源:[J].Advances in Therapy(IF 2.125), 2015, Vol.32 (6), pp.510-522Springer
摘要:Abstract(#br) Background(#br)The oral, potent poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, is well tolerated at doses of ≤400 mg twice daily (BID) (administered as capsules), and has shown efficacy in patients with advanced BRCA -mutated ovarian and breast cancer....
作者:Laurence Gladieff , Dominique Stoppa Lyonnet , Alain Lortholary ...
来源:[J].Bulletin du Cancer(IF 0.605), 2017, Vol.104, pp.S16-S23Elsevier
摘要:... Today, olaparib is indicated for patients with a high grade serous ovarian or fallopian tube or peritoneum adenocarcinoma, with deleterious mutation of BRCA genes (constitutional or somatic), and in sensitive platinum relapse, and in maintenance therapy after a response to ch...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×